Prothena (Group)

https://www.prothena.com

Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding and cell adhesion, particularly on the discovery, development and commercialization of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in inflammatory disease and metastatic cancers (PRX003). Prothena conducts its operations through its wholly- owned subsidiaries, Neotope Biosciences Limited, Onclave Therapeutic Limited and Prothena Biosciences Inc. *

	Start	2012-12-21 splitoff
	Predecessor	Élan Corporation, plc
	Industry	CNS drug (neurological drug)
	Industry 2	drug discovery
	Person	Kinney, Gene G. (Prothena 201610– CEO before COO + CSO before Élan)
	Person 2	Nguyen, Tran (Prothena 201701 CFO)

	Region	Dublin
	Country	Ireland, Republic of
	Street	25–28 North Wall Quay
	City	Dublin 1
	Tel	+353-1-902-3519
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	1,055,000 (revenue, total, consolidated (2016) 2016-12-31)
	Profit	-160,108,000 (2016-12-31)
	Cash	386,923,000 (2016-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]